First pill for blinding eye disease enters human testing
NCT ID NCT07408232
Summary
This is the first study in people for an oral medication called OCT-980, designed to treat a specific genetic form of retinitis pigmentosa, an inherited disease that causes progressive vision loss. The study will first test single doses in healthy volunteers to check safety, then give multiple doses for up to 48 weeks to people with the disease to see if it is safe, how the body processes it, and if it might help slow vision loss. There is currently no approved treatment or cure for this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX Clinical Research Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.